China FDA orders respiratory API recalled after 'fur' like impurities found

SINGAPORE--The China FDA ordered Shandong Qidu Pharmaceutical to recall 21,700 bottles of an injectable API combination for treating respiratory, urinary and reproductive infections. The agency said impurities "similar to furs" were found in sampled bottles.

The recalled combination was levofloxacin and sodium, the CFDA said, and the head of the company was "invited" for a talk, the official news agency, Xinhua, reported. The last name found as the CEO of the company was Zheng JiaDing.

The news service said the company, which calls itself one of the top suppliers of IV fluids in China, has admitted it was negligent and took full responsibility for the problem. The combination drug was sold in four of China's provinces.

- here's the Xinhua story

Suggested Articles

McCallum was hit with a warning letter from the FDA for testing issues with its products and failing to keep appropriate records.

The FDA made public a voluntary recall of sterile injectables made by Coastal Meds of Mississippi, after visible particles were found in some vials.

The FDA hit New Jersey-based CMO Tris Pharma with a warning letter, citing significant violations.